-transparent.png){kind=logo}
Since 1971 pyrimethamine-sulfadoxine (Fansidar, Roche) has been used worldwide for prophylaxis and therapy of chloroquine resistant Plasmodium falciparum malaria. The drug monitoring team of the producing firm has received reports of a number of cutaneous adverse reactions, some severe, and a few even with fatal outcome. Liver reactions were also encountered, with severe cases only in the recent literature. We report on two patients with hepatitis in temporal relationship to pyrimethamine-sulfadoxine, the first with a second event after later exposure to the same drug. After discontinuing the medication the liver function abnormalities returned to normal limits within a few weeks. Liver biopsy and a positive lymphocyte transformation test against sulfadoxine, a component of Fansidar, strongly suggest that Fansidar was the cause of hepatic injury.
P Meier, and
M Schmid, and
M Stäubli
September 1997,
Minerva cardioangiologica,
P Meier, and
M Schmid, and
M Stäubli
October 1987,
Schweizerische medizinische Wochenschrift,
P Meier, and
M Schmid, and
M Stäubli
January 1982,
The American journal of the medical sciences,
P Meier, and
M Schmid, and
M Stäubli
January 2007,
Scandinavian journal of rheumatology,
P Meier, and
M Schmid, and
M Stäubli
February 1983,
Revista espanola de las enfermedades del aparato digestivo,
P Meier, and
M Schmid, and
M Stäubli
October 1986,
Human pathology,
P Meier, and
M Schmid, and
M Stäubli
September 1981,
Vox sanguinis,
P Meier, and
M Schmid, and
M Stäubli
January 1987,
Chemotherapy,
P Meier, and
M Schmid, and
M Stäubli
March 1999,
Journal of hepatology,
P Meier, and
M Schmid, and
M Stäubli
September 2000,
Digestive diseases and sciences,
